Malignant potential of Barrett's esophagus: Special reference to HDAC-1 and MTA-1 expression

Hepato-Gastroenterology

Volumn 58, Issue 106, 2011, Pages 472-476

  Miyatani, Tomohiko ^a   Kurita, Nobuhiro ^a   Mikami, Chie ^a   Kashihara, Hideya ^a   Higashijima, Jun ^a   Yoshikawa, Kozo ^a   Nishioka, Masanori ^a   Sato, Hirohiko ^a   Iwata, Takashi ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Barrett's esophagus; HDAC 1; Low grade dysplasia management; MTA 1

Indexed keywords

HISTONE DEACETYLASE 1; METASTASIS ASSOCIATED PROTEIN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-7; REPRESSOR PROTEINS;

EID: 79958106066     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Peters JH, Hagen JA, DeMeester SR: Barrett's esophagus. J Gastrointest Surg 2004; 8:1-17.
2. Reid BJ: Barrett's esophagus and adenocarcinoma. Gastroenterol Clin North Am 1991; 20:817-834.
3. Shaheen N, Ransohoff DR: Gastroesophageal reflux, Barrett's esophagus and esophageal cancer. JAMA 2002; 287:1972-1981.
4. Haggitt RC: Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol 1992; 23:475-476.
5. Blot WJ, Devesa SS, Fraumeni JF Jr: Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270:1320. (Pubitemid 23267889)
6. rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS et al: Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92:118-124.
7. Stathopoulos GP, Tsiaras N: Epidemiology and pathogenesis of esophageal cancer: Management and its controversial results (review). Oncol Rep 2003; 10:449-454.
8. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-2053. (Pubitemid 28525384)
9. Shaheen NJ: Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005; 128:1554-1566.
10. Daly JM, Karnell LH, Menck HR: National Cancer Data Base report on esophageal carcinoma. Cancer 1996; 78:1820-1828. (Pubitemid 26330913)
11. Ide H, Nakamura T, Hayashi K, et al: Esophageal squamous cell carcinoma: pathology and prognosis. World J Surg 1994; 18:321-330. (Pubitemid 24215028)
12. Torres C, Turner JR, Wang HH, et al: Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients. Cancer. 1999; 85:520-528. (Pubitemid 29075273)
13. Drewitz DJ, Sampliner RE, Garewal HS: The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215. (Pubitemid 27076463)
14. Sampliner RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-1895.
15. Ling FC, Baldus SE, Khochfar J, Xi H, Neiss S, Brabender J, Metzger R, Drebber U, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM: Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer. Histopathology 2007; 50:203-209. (Pubitemid 46046388)
16. Keswani RN, Noffsinger A, Waxman I, Bissonnette M: Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2006; 15(7): 1243-1249. (Pubitemid 44125276)
17. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N: Screening and surveillance for Barrett esophagus in high-risk groups: a costutility analysis Ann Intern Med 2003; 138:176-186.
18. Spechler SJ: Should patients with GERD be screened once at least for Barrett's epithelium? A balancing view: to screen or not to screen: scoping out the issues. Am J Gastroenterol 2004; 99:2295-2296.
19. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999; 13:1924-1935. (Pubitemid 29407360)
20. Kingston RE, Narlikar GJ: ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev 1999; 13:2339-2352. (Pubitemid 29453604)
21. Urnov FD, Wolffe AP: Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001; 20:2991-3006 (Pubitemid 32553553)
22. Hong L, Schroth GP, Matthews HR, Yau P, Bradbury EM: Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. J Biol Chem 1993; 268:305-314.
23. Cress WD, Seto E: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184:1-16. (Pubitemid 30349623)
24. Knoepfler PS, Eisenman RN: Sin meets NuRD and other tails of repression. Cell 1999; 99:447-450.
25. Iwata T, Kurita N, Nishioka M, Hidenori M, Wakatsuki S, Sano T, Shimada M: Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach. Hepato-gatsroenterol 2007; 54:1710-1712. (Pubitemid 350068460)
26. Odze RD: Oesophagus Diagnosis and grading of dysplasia in Barrett's. J Clin. Pathol 2006; 59:1029-1038.
27. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D: The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998; 95: 279-289. (Pubitemid 28473788)
28. Yao Y-L, Yang W-M: The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Bio Chemistry 2003; 43:42560-42568. (Pubitemid 37310529)
29. Toh Y, Pencil SD, Nicolson GL: A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol. Chem 1994; 269:22958-22963.
30. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicolson GL, Sugimachi K: Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Intl J Cancer 1997; 74:459-463. (Pubitemid 27400170)
31. Toh Y, Kuwano H, Mori M, Nicolson GL, Sugimachi K: Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 1999; 79:1723-1726. (Pubitemid 29132295)
32. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA: The role of metastasis-associated protein 1 in prostate cancer progression. Caner Res 2004; 64:825-829. (Pubitemid 38176879)
33. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92:1300-1304.
34. Stuart JS: Barrett's esophagus. N Engl J Med 2002; 346:836-842.
35. Spechler SJ: Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2005; 100:927-935.